Meeting
2018 ASCO Annual Meeting
Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.
Authors
Shukui Qin
Nanjing Bayi Hospital, Nanjing, China
Shukui Qin , Weijian Guo , Jian-Ming Xu , Qi Li , Ying Cheng , Tian Shu Liu , Jiongjie Chen , Wen-Feng Chen , Jin Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01228734
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3521)
DOI
10.1200/JCO.2018.36.15_suppl.3521
Abstract #
3521
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.
First Author: Tanios S. Bekaii-Saab
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2019 Gastrointestinal Cancers Symposium
Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX/FOLFIRI plus cetuximab.
First Author: S.P. Somashekhar